Todd W. Miller

Dr. Todd W. Miller is a Professor in the Department of Pharmacology and Toxicology at the Medical College of Wisconsin and a member of the institution's Cancer Center. His research program focuses on understanding and overcoming therapy resistance in breast cancer, particularly ER+ and triple-negative subtypes.

Dr. Miller's research interests center on the molecular mechanisms of endocrine therapy resistance in breast cancer. His laboratory investigates how metabolic reprogramming, epigenetic alterations, and signaling pathway adaptations (particularly the PI3K/AKT/mTOR pathway) contribute to treatment failure. Recent work has revealed oxidative phosphorylation as a metabolic vulnerability in therapy-tolerant persister cells, demonstrated how chromatin remodeling can overcome chemoresistance, and identified novel strategies for treating endocrine-resistant disease through alternating hormone therapies.

Analysis of Dr. Miller's recent publications (2020-2025) reveals a strong focus on translational breast cancer research with significant clinical implications. His work spans basic molecular mechanisms to clinical applications, with particular emphasis on epigenetic regulation, metabolic adaptations in resistant cells, and rational combination therapies. The research demonstrates increasing sophistication in integrating molecular profiling with therapeutic response, reflecting the evolution toward precision medicine in breast cancer treatment.

• Extensive work on PI3K/AKT/mTOR pathway in therapy resistance
• Pioneering research on metabolic vulnerabilities in persister cells
• Development of novel endocrine therapy strategies for resistant disease
• Investigation of epigenetic mechanisms in treatment resistance

Dr. Miller actively collaborates with clinical researchers through the Molecular Tumor Board at Dartmouth-Hitchcock Medical Center, demonstrating his commitment to translating basic findings into clinical practice. His laboratory appears to focus on identifying biomarkers that predict response to targeted therapies and developing rational combination approaches to overcome resistance mechanisms. The research program maintains strong connections between basic science discovery and clinical application, with several findings having direct implications for breast cancer treatment strategies.